Vivani Medical (VANI) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 10, 2021
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-36747
Entity Registrant Name	Second Sight Medical Products, Inc.
Entity Central Index Key	0001266806
Entity Tax Identification Number	02-0692322
Entity Incorporation, State or Country Code	CA
Entity Address, Address Line One	13170 Telfair Avenue
Entity Address, City or Town	Sylmar
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91342
City Area Code	(818)
Local Phone Number	833-5000
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		39,409,176
Common Stock [Member]
Title of 12(b) Security	Common Stock
Trading Symbol	EYES
Security Exchange Name	NASDAQ
Warrants [Member]
Title of 12(b) Security	Warrants
Trading Symbol	EYESW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 72,028	$ 3,177
Prepaid expenses and other current assets	1,193	1,092
Total current assets	73,221	4,269
Property and equipment, net	117	174
Right-of-use assets, net	270
Deposits and other assets	22	17
Total assets	73,630	4,460
Current liabilities:
Accounts payable	758	486
Accrued expenses	1,073	875
Accrued compensation expense	575	173
Accrued clinical trial expenses	999	1,063
Current operating lease liabilities	179
Current debt		2,200
Contract liabilities	335	335
Total current liabilities	3,919	5,132
Long term operating lease liabilities	102
Total liabilities	4,021	5,132
Stockholders’ equity (deficit):
Preferred stock, no par value, 10,000 shares authorized; none outstanding
Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 39,409 and 23,214 as of September 30, 2021 and December 31, 2020, respectively	347,940	270,126
Additional paid-in capital	49,371	49,314
Accumulated other comprehensive loss	(400)	(448)
Accumulated deficit	(327,302)	(319,664)
Total stockholders’ equity (deficit)	69,609	(672)
Total liabilities and stockholders’ equity	$ 73,630	$ 4,460

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares shares in Thousands, $ / shares in Thousands	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred Stock, No Par Value	$ 0	$ 0
Preferred Stock, Shares Authorized	10,000	10,000
Preferred Stock, Shares Outstanding	0	0
Common Stock, No Par Value	$ 0	$ 0
Common Stock, Shares Authorized	300,000	300,000
Common Stock, Shares, Issued	39,409	39,409
Common Stock, Shares, Outstanding	23,214	23,214

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Net sales
Cost of sales
Gross profit
Operating expenses:
Research and development, net of grants	697	279	1,726	4,489
Clinical and regulatory, net of grants	276	261	576	1,604
Selling and marketing				701
General and administrative	1,530	1,062	5,340	4,599
Restructuring charges				2,229
Total operating expenses	2,503	1,602	7,642	13,622
Loss from operations	(2,503)	(1,602)	(7,642)	(13,622)
Other income (expense), net	2	(1)	4	33
Net loss	$ (2,501)	$ (1,603)	$ (7,638)	$ (13,589)
Net loss per common share – basic and diluted	$ (0.06)	$ (0.07)	$ (0.25)	$ (0.69)
Weighted average common shares outstanding – basic and diluted	39,409	23,118	30,596	19,714

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Net loss	$ (2,501)	$ (1,603)	$ (7,638)	$ (13,589)
Other comprehensive income (loss):
Foreign currency translation adjustments	(13)	35	48	64
Comprehensive loss	$ (2,514)	$ (1,568)	$ (7,590)	$ (13,525)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 264,008	$ 48,613	$ (562)	$ (304,784)	$ 7,725
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2019	15,643
Repurchase of fractional shares in connection with reverse stock split	$ (11)				(11)
Repurchase of fractional shares in connection with reverse stock splitIn shares	(2)
Issuance of shares of common stock	$ 6				6
Stock Issued During Period, Shares, New Issues	1
Stock-based compensation expense		279			279
Net loss				(8,886)	(8,886)
Foreign currency translation adjustment			19		19
Common Stock, Shares, Outstanding, Ending Balance at Mar. 31, 2020	15,657
Ending balance, value at Mar. 31, 2020	$ 264,003	48,892	(543)	(313,670)	(1,318)
Beginning balance, value at Dec. 31, 2019	$ 264,008	48,613	(562)	(304,784)	7,725
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2019	15,643
Net loss					(13,589)
Foreign currency translation adjustment					64
Ending balance, value at Sep. 30, 2020	$ 270,126	49,287	(498)	(318,373)	542
Beginning balance, value at Mar. 31, 2020	$ 264,003	48,892	(543)	(313,670)	(1,318)
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2020	15,657
Stock-based compensation expense		88			88
Net loss				(3,100)	(3,100)
Foreign currency translation adjustment			10		10
Common Stock, Shares, Outstanding, Ending Balance at Jun. 30, 2020	23,118
Issuance of shares of common stock and warrants in connection with share offering, net of issuance costs	$ 6,393	280			6,673
[custom:StockIssuedDuringPeriodSharesCommonStockAndWarrantsInConnectionWithRightsOfferingNetOfIssuanceCosts]	7,500
Repurchase of ESSP shares as part of rescission offer	$ (270)				(270)
Stock Repurchased and Retired During Period, Shares	(39)
Ending balance, value at Jun. 30, 2020	$ 270,126	49,260	(533)	(316,770)	2,083
Stock-based compensation expense		27			27
Net loss				(1,603)	(1,603)
Foreign currency translation adjustment			35		35
Ending balance, value at Sep. 30, 2020	270,126	49,287	(498)	(318,373)	542
Beginning balance, value at Dec. 31, 2020	$ 270,126	49,314	(448)	(319,664)	$ (672)
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2020	23,214				23,214
Stock-based compensation expense		19			$ 19
Net loss				(2,843)	(2,843)
Foreign currency translation adjustment			36		36
Common Stock, Shares, Outstanding, Ending Balance at Mar. 31, 2021	27,908
Ending balance, value at Mar. 31, 2021	$ 294,592	49,333	(412)	(322,507)	21,006
Issuance of shares of common stock in underwritten public offering	$ 24,451				24,451
Stock issued during period shares common stock in underwritten public offering	4,650
Warrants exercised	$ 15				15
Stock issued during period shares stock options warrants exercised	44
Beginning balance, value at Dec. 31, 2020	$ 270,126	49,314	(448)	(319,664)	$ (672)
Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2020	23,214				23,214
Net loss					$ (7,638)
Foreign currency translation adjustment					$ 48
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2021	39,409				23,214
Ending balance, value at Sep. 30, 2021	$ 347,940	49,371	(400)	(327,302)	$ 69,609
Beginning balance, value at Mar. 31, 2021	$ 294,592	49,333	(412)	(322,507)	21,006
Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2021	27,908
Stock-based compensation expense		19			19
Net loss				(2,294)	(2,294)
Foreign currency translation adjustment			25		25
Common Stock, Shares, Outstanding, Ending Balance at Jun. 30, 2021	39,409
Ending balance, value at Jun. 30, 2021	$ 347,940	49,352	(387)	(324,801)	72,104
Issuance of shares of common stock in underwritten public offering	$ 53,338				53,338
Stock issued during period shares common stock in underwritten public offering	11,500
Warrants exercised	$ 10				10
Stock issued during period shares stock options warrants exercised	1
Stock-based compensation expense		19			19
Net loss				(2,501)	(2,501)
Foreign currency translation adjustment			(13)		$ (13)
Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2021	39,409				23,214
Ending balance, value at Sep. 30, 2021	$ 347,940	$ 49,371	$ (400)	$ (327,302)	$ 69,609

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (7,638)	$ (13,589)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	57	148
Stock-based compensation	57	394
Non-cash lease expense	11	3
Restructuring charges-inventory and fixed asset impairment		1,116
Changes in operating assets and liabilities:
Accounts receivable		461
Inventories		218
Prepaid expenses and other assets	(106)	(568)
Accounts payable	253	(1,256)
Accrued expenses	266	64
Accrued compensation expenses	401	(2,360)
Accrued clinical trial expenses	(64)
Net cash used in operating activities	(6,763)	(15,369)
Cash flows from investing activities:
Sale of assets held for sale		398
Purchases of property and equipment		(331)
Net cash used in investing activities		67
Cash flows from financing activities:
Net proceeds from sale of common stock and/or warrants	77,814	6,679
Repayment of debt	(2,200)
Repurchase of ESPP shares and fractional shares in connection with reverse stock split		(281)
Net cash provided by financing activities	75,614	6,398
Effect of exchange rate changes on cash and cash equivalents		14
Cash and cash equivalents:
Net increase (decrease)	68,851	(8,890)
Balance at beginning of period	3,177	11,327
Balance at end of period	72,028	2,437
Supplemental disclosures of cash flow information:
Interest	$ 135

Organization and Business Opera

Organization and Business Operations	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	1. Organization and Business Operations Second Sight Medical Products, Inc. (“Second Sight,” the “Company,” “we,” “us,” “our” or similar terms) has developed, manufactured and marketed implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. We are a recognized global leader in neuromodulation devices for blindness, and are committed to developing new technologies to treat the broadest population of sight-impaired individuals. Our principal offices are located in Los Angeles, California. In 2007, Second Sight formed Second Sight Medical Products (Switzerland) Sàrl, initially to manage clinical trials and sales and marketing in Europe, the Middle East and Asia-Pacific, and more recently for the research of future technologies. As the laws of Switzerland require at least two corporate stockholders, Second Sight Medical Products (Switzerland) Sàrl is 99.5 0.5 100 Leveraging our 20 years of experience in neuromodulation for vision, we are developing the Orion ® ● We have a good safety profile ● The efficacy data is encouraging No peer-reviewed data is available yet for the Orion system. We are currently negotiating the clinical and regulatory pathway to commercialization with the FDA as part of the Breakthrough Devices Program. One subject in the Early Feasibility study had the Orion device explanted on August 9, 2021. The explant was due to the need for an MRI to diagnose a condition unrelated to the Orion device. Product and Clinical Development Plans By further developing our visual cortical prosthesis, Orion, we believe we may be able to significantly expand our market to include nearly all profoundly blind individuals. The principal notable exceptions for potential use of the Orion are those who are blind due to otherwise currently treatable diseases, individuals who are born blind, or blindness due to direct damage of the visual cortex, which is rare. Of the estimated 36 million blind people worldwide, there are approximately 5.8 million people who are legally blind due to causes that are not otherwise treatable. We continue to develop and refine our estimates of the potential addressable market size as we evaluate the commercial prospects for Orion using a combination of published sources, third party market research, and physician feedback. We currently estimate over 500,000 individuals in the US are legally blind due to retinitis pigmentosa, glaucoma, diabetic retinopathy, optic nerve disease and eye injury. Of this population, we estimate the potential US addressable market is between 50,000 and 100,000 individuals with bi-lateral blindness at the light-perception level or worse. Our marketing approvals by the FDA and other regulatory agencies will ultimately determine the subset of these patients who are eligible for the Orion based on our clinical trials and the associated results. Our objective in designing and developing the Orion visual prosthesis system is to bypass the optic nerve and directly stimulate the part of the brain responsible for human vision. A six-subject Early Feasibility Study of the Orion device is currently underway at UCLA and Baylor. Our 36 month results indicate a good safety profile with encouraging efficacy data and benefits in helping subjects perform their daily living tasks. We believe these data results are encouraging and support advancement of Orion into a larger pivotal clinical study. Early promising results are not necessarily indicative of results that may be obtained in our larger Orion clinical trials. In November 2017, the FDA granted Breakthrough Devices Program designation for the Orion. This designation is given to a few select medical devices in order to provide more effective treatment of life-threatening or irreversibly debilitating diseases or conditions. This program is intended to help patients have more timely access to these medical devices by expediting their development, assessment, and review. On February 26, 2021, the U.S. Food and Drug Administration (FDA) approved the Argus 2s Retinal Prosthesis System, a redesigned set of external hardware (glasses and video processing unit) initially for use in combination with previously implanted Argus II systems for the treatment of retinitis pigmentosa (RP). The Company expects that the Argus 2s will be adapted to be the external system for the next generation Orion Visual Cortical Prosthesis System currently under development. In addition to ergonomic improvements, the Argus 2s system offers significantly more processing power, potentially allowing for improved video processing. Liquidity and Capital Resources From inception, our operations have been funded primarily through the sales of our common stock and warrants, as well as from the issuance of debt, convertible debt, research and clinical grants, and limited product revenue generated from the sale of our Argus II product. Funding of our business since 2019 has been primarily provided by: ● On June 25, 2021, we closed an underwritten public offering of 11,500,000 5.00 53.3 ● On March 23, 2021, we closed our private placement to seven institutional investors of 4,650,000 6.00 24.5 ● On December 8, 2020, we borrowed $ 1 1.2 million two ● On May 5, 2020, we closed our underwritten public offering of 7,500,000 1.00 6.7 million We were awarded a $ 1.6 6.4 1.4 1.4 0.3 million 1.1 million 0.4 million 1.0 million Our financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We estimate that currently available cash will provide sufficient funds to enable the Company to meet its planned obligations for at least eighteen months. Our ability to continue as a going concern is dependent on our ability to develop profitable operations through implementation of our business initiatives and/or raise additional capital, however, there can be no assurances that we will be able to do so. We were notified by the Nasdaq stock market on July 23, 2020 regarding our non-compliance with one of the continued listing requirements of the Nasdaq Capital Market. We have subsequently satisfied the Nasdaq compliance listing requirement.

Basis of Presentation, Signific

Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements	2. Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements Basis of Presentation These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. The balance sheet as of December 31, 2020 has been derived from our audited balance sheet included in our annual report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on March 16, 2021. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2020, contained in our Annual Report on Form 10-K. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period. Reverse Stock Split On December 31, 2019 we effected a reverse stock split of the outstanding shares of our no par value common stock and outstanding warrants to purchase our common stock by a ratio of 1-for-8 The accompanying consolidated financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock, restricted stock units, and per share amounts contained in our consolidated financial statements have been retrospectively adjusted. Significant Accounting Policies Segment Reporting. On March 31, 2020, due to the COVID-19 pandemic and related inability to secure additional funding, we laid off the majority of our employees and reduced our operating expenses significantly to allow for our continuing business operations. In the nine months ended September 30, 2020, due to our focus on Orion and wind down of selling and marketing activities related to Argus II, we recorded impairment charges to our inventory of $ 0.5 million 0.7 million 0.2 Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020. Recently Issued Accounting Pronouncements We do not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

Concentration of Risk

Concentration of Risk	9 Months Ended
	Sep. 30, 2021
Risks and Uncertainties [Abstract]
Concentration of Risk	3. Concentration of Risk Credit Risk Financial instruments that subject us to concentrations of credit risk consist primarily of cash and money market funds. We maintain cash and money market funds with financial institutions that we deem reputable. Foreign Operations The accompanying condensed consolidated financial statements as of September 30, 2021 and December 31, 2020 include assets amounting to $ 32,000 18,000

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. Cash equivalents, which includes money market funds, are the only financial instrument measured and recorded at fair value on our consolidated balance sheet, and they are valued using Level 1 inputs. Assets measured at fair value on a recurring basis are as follows Total Level 1 Level 2 Level 3 September 30, 2021 (unaudited): Money market funds $ 71,970 $ 71,970 $ — $ — December 31, 2020: Money market funds $ 3,122 $ 3,122 $ — $ —

Selected Balance Sheet Detail

Selected Balance Sheet Detail	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Selected Balance Sheet Detail	5. Selected Balance Sheet Detail Property and equipment, net Property and equipment consisted of the following (in thousands): September 30, December 31, 2021 2020 Laboratory equipment $ 584 $ 584 Computer hardware and software 69 69 653 653 Accumulated depreciation and amortization (536 ) (479 ) Property and equipment, net $ 117 $ 174 As a result of our decision to cease marketing of Argus II we recorded an impairment of $0.7 million during the nine month period ended September 30, 2020 related to our fixed assets. Debt On December 8, 2020, we borrowed $ 1 12 Contract Liabilities Contract liabilities consisted of the following (in thousands): Beginning balance as of December 31, 2020 $ 335 Consideration received in advance of revenue recognition — Revenue recognized — Ending balance as of September 30, 2021 $ 335 Product Warranties A summary of activity of our warranty liabilities, which are included in accrued expenses, for the period ended September 30, 2021 is presented below: Beginning balance as of December 31, 2020 $ 200 Additions — Settlements — Adjustments and other (7 ) Ending balance as of September 30, 2021 $ 193 Right-of-use assets and operating lease liabilities We lease certain office space and equipment for our use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease costs are recognized in the income statement over the lease term on a straight-line basis. Depreciation is computed using the straight-line method over the estimated useful life of the respective assets. The depreciable life of assets and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. As most of our leases do not provide an implicit rate, we used our estimated incremental borrowing rate of 10 On May 18, 2020 we entered into a Letter Agreement with Sylmar Biomedical Park, LLC (the “Landlord”), pursuant to which the parties agreed to accelerate the expiration dates of our existing leases (the “Leases”), to a date no later than June 18, 2020 210,730 150,000 0.9 2.3 150,000 On January 22, 2021, we entered into a lease agreement, effective February 1, 2021, to sub-lease office space to replace our existing headquarters. We pay $ 17,000 17,500 17,290 The sub-lease is for two years and two months. The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company’s right-of-use assets and related lease liabilities are as follows (in thousands, except for remaining lease term and discount rate): Year ending December 31: 2021 (3 months remaining) $ 51 2022 201 2023 52 Total lease payments 304 Less imputed interest (23 ) Total lease liabilities $ 281 Other supplemental information: Current operating lease liabilities $ 179 Long term operating lease liabilities 102 Total lease liabilities $ 281 Discount rate 10 % For the three months ended September 30, 2021 For the three months ended September 30, 2020 For the nine months ended September 30, 2021 For the nine months ended September 30, 2020 Cash paid for operating lease liabilities $ 51 $ 48 119 275 Rent expense, including common area maintenance charges, was $ 146,000 277,000

Equity Securities

Equity Securities	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Equity Securities	6. Equity Securities Potentially Dilutive Common Stock Equivalents As of September 30, 2021 and 2020, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive September 30, 2021 2020 Common stock warrants issued to underwriter in connection with May 2020 offering 10 375 Common stock warrants issued in connection with March 2017 rights offering 1,706 1,706 Common stock warrants issued in connection with February 2019 rights offering 5,975 5,976 Common stock options 182 265 7,873 8,322

Warrants

Warrants	9 Months Ended
	Sep. 30, 2021
Warrants
Warrants	7. Warrants On February 22, 2019, we completed a registered rights offering to existing stockholders in which we sold approximately 5,976,000 5.792 11.76 five On March 6, 2017, we completed a registered rights offering to existing stockholders in which we sold approximately 1,706,000 11.76 We extended the term of 1.7 two 1.6 2.50 2.49 81 82 0 Upon close of our May 2020 registered offering we issued 375,000 1.25 May 5, 2025 10,125 A summary of warrants activity for the nine months ended September 30, 2021 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Warrants outstanding as of December 31, 2020 7,759 $ 11.66 3.21 Issued — Exercised (68 ) 1.45 Forfeited or expired — Warrants outstanding as of September 30, 2021 7,691 $ 11.75 2.46 Warrants exercisable as of September 30, 2021 7,691 $ 11.75 2.46 The warrants outstanding as of September 30, 2021 had $20,000 in intrinsic value.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the nine months ended September 30, 2021 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Options outstanding as of December 31, 2020 196 $ 15.48 7.65 Granted — $ — Exercised — $ — Forfeited or expired (14 ) $ 12.95 Options outstanding and expected to vest as of September 30, 2021 182 $ 15.68 6.84 Options exercisable as of September 30, 2021 143 $ 18.82 6.45 The estimated aggregate intrinsic value of stock options exercisable as of September 30, 2021 was $ 15,000 105,000 2.29 We adopted an employee stock purchase plan in June 2015 for all eligible employees. At September 30, 2021 the available number of shares that may be issued under the plan is 77,031 Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 was as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development $ 5 $ 11 $ 15 $ 120 Clinical and regulatory 9 12 27 39 Selling and marketing — — — 41 General and administrative 5 4 15 194 Total $ 19 $ 27 $ 57 $ 394

Risk and Uncertainties

Risk and Uncertainties	9 Months Ended
	Sep. 30, 2021
Risk And Uncertainties
Risk and Uncertainties	9. Risk and Uncertainties COVID-19 has directly and indirectly adversely affected Second Sight and will likely continue to do so for an uncertain period of time. In March and April 2020 we laid off a substantial majority of our employees as a result of COVID-19 and an inability to obtain financing. We currently employ 15 employees to oversee current operations. The cumulative effects of COVID-19 on the Company cannot be predicted at this time, but could include, without limitation: ● reputational damages of the Company and its products; ● inability to raise additional funds to finance and continue our operations; ● inability to maintain adequate facilities; ● inability to retain and hire experienced personnel; ● inability to finalize our plan for and enroll patients into our proposed pivotal clinical trial; ● material delays or inability to complete development and commercialization of Orion; ● inability to satisfy Nasdaq’s continued listing requirements and exposure to delisting if not remedied; and ● other uncertain events that may have negative impact effect on our operations.

Litigation, Claims and Assessme

Litigation, Claims and Assessments	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Litigation, Claims and Assessments	10. Litigation, Claims and Assessments Four oppositions filed by Pixium Vision are pending in the European Patent Office, each challenging the validity of a European patent owned by us. The outcomes of the challenges are not certain, however, if successful, they may affect our ability to block competitors from utilizing our patented technology. We believe a successful challenge will not have a material effect on our ability to manufacture and sell our products, or otherwise have a material effect on our operations. As described in the Company’s 10-K for the year ended December 31, 2020, the Company had entered into a Memorandum of Understanding (“MOU”) for a proposed business combination with Pixium Vision SA (“Pixium”). In response to a press release by Pixium dated March 24, 2021, and subsequent communications between us and Pixium, our Board of Directors determined that the business combination with Pixium was not in the best interest of our shareholders. On April 1, 2021, we gave notice to Pixium that we were terminating the MOU between the parties and seeking an amicable resolution of termination amounts that may be due, however no assurance can be given that an amicable resolution will be reached. We accrued $ 1,000,000 1,000,000 5,217,659.60 6,162,760 In November 2020, we and Pixium retained Oppenheimer & Co. Inc. as placement agent for a proposed private placement of securities in connection with the Business Combination. On April 1, 2021, we received an invoice from Oppenheimer for more than $ 1.86 million 6.5 27.9 million On or about July 19, 2021 Martin Sumichrast filed a complaint with the Superior Court of the State of California, County of Los Angeles—Central District, claiming that he is entitled to compensation for services, as well as exemplary and other damages in an amount to be determined at trial but not less than $ 2 million We are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not have a material effect on our results of operations, however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Basis of Presentation, Signif_2

Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. The balance sheet as of December 31, 2020 has been derived from our audited balance sheet included in our annual report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on March 16, 2021. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2020, contained in our Annual Report on Form 10-K. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.
Reverse Stock Split	Reverse Stock Split On December 31, 2019 we effected a reverse stock split of the outstanding shares of our no par value common stock and outstanding warrants to purchase our common stock by a ratio of 1-for-8 The accompanying consolidated financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock, restricted stock units, and per share amounts contained in our consolidated financial statements have been retrospectively adjusted.
Significant Accounting Policies	Significant Accounting Policies Segment Reporting. On March 31, 2020, due to the COVID-19 pandemic and related inability to secure additional funding, we laid off the majority of our employees and reduced our operating expenses significantly to allow for our continuing business operations. In the nine months ended September 30, 2020, due to our focus on Orion and wind down of selling and marketing activities related to Argus II, we recorded impairment charges to our inventory of $ 0.5 million 0.7 million 0.2 Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements We do not believe that any recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Assets measured at fair value on a recurring basis are as follows	Assets measured at fair value on a recurring basis are as follows Total Level 1 Level 2 Level 3 September 30, 2021 (unaudited): Money market funds $ 71,970 $ 71,970 $ — $ — December 31, 2020: Money market funds $ 3,122 $ 3,122 $ — $ —

Selected Balance Sheet Detail (

Selected Balance Sheet Detail (Tables)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Property and equipment consisted of the following (in thousands):	Property and equipment consisted of the following (in thousands): September 30, December 31, 2021 2020 Laboratory equipment $ 584 $ 584 Computer hardware and software 69 69 653 653 Accumulated depreciation and amortization (536 ) (479 ) Property and equipment, net $ 117 $ 174
Contract liabilities consisted of the following (in thousands):	Contract liabilities consisted of the following (in thousands): Beginning balance as of December 31, 2020 $ 335 Consideration received in advance of revenue recognition — Revenue recognized — Ending balance as of September 30, 2021 $ 335
A summary of activity of our warranty liabilities, which are included in accrued expenses, for the period ended September 30, 2021 is presented below:	A summary of activity of our warranty liabilities, which are included in accrued expenses, for the period ended September 30, 2021 is presented below: Beginning balance as of December 31, 2020 $ 200 Additions — Settlements — Adjustments and other (7 ) Ending balance as of September 30, 2021 $ 193
The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company’s right-of-use assets and related lease liabilities are as follows (in thousands, except for remaining lease term and discount rate):	The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company’s right-of-use assets and related lease liabilities are as follows (in thousands, except for remaining lease term and discount rate): Year ending December 31: 2021 (3 months remaining) $ 51 2022 201 2023 52 Total lease payments 304 Less imputed interest (23 ) Total lease liabilities $ 281 Other supplemental information: Current operating lease liabilities $ 179 Long term operating lease liabilities 102 Total lease liabilities $ 281 Discount rate 10 % For the three months ended September 30, 2021 For the three months ended September 30, 2020 For the nine months ended September 30, 2021 For the nine months ended September 30, 2020 Cash paid for operating lease liabilities $ 51 $ 48 119 275

Equity Securities (Tables)

Equity Securities (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
As of September 30, 2021 and 2020, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive	As of September 30, 2021 and 2020, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive September 30, 2021 2020 Common stock warrants issued to underwriter in connection with May 2020 offering 10 375 Common stock warrants issued in connection with March 2017 rights offering 1,706 1,706 Common stock warrants issued in connection with February 2019 rights offering 5,975 5,976 Common stock options 182 265 7,873 8,322

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
Warrants
A summary of warrants activity for the nine months ended September 30, 2021 is presented below (in thousands, except per share and contractual life data).	A summary of warrants activity for the nine months ended September 30, 2021 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Warrants outstanding as of December 31, 2020 7,759 $ 11.66 3.21 Issued — Exercised (68 ) 1.45 Forfeited or expired — Warrants outstanding as of September 30, 2021 7,691 $ 11.75 2.46 Warrants exercisable as of September 30, 2021 7,691 $ 11.75 2.46

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the nine months ended September 30, 2021 is presented below (in thousands, except per share and contractual life data).	A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the nine months ended September 30, 2021 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Options outstanding as of December 31, 2020 196 $ 15.48 7.65 Granted — $ — Exercised — $ — Forfeited or expired (14 ) $ 12.95 Options outstanding and expected to vest as of September 30, 2021 182 $ 15.68 6.84 Options exercisable as of September 30, 2021 143 $ 18.82 6.45
Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 was as follows (in thousands):	Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 was as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development $ 5 $ 11 $ 15 $ 120 Clinical and regulatory 9 12 27 39 Selling and marketing — — — 41 General and administrative 5 4 15 194 Total $ 19 $ 27 $ 57 $ 394

Organization and Business Ope_2

Organization and Business Operations (Details Narrative) - USD ($) $ / shares in Thousands	Jun. 25, 2021	May 12, 2021	Apr. 06, 2021	Mar. 23, 2021	Dec. 08, 2020	May 05, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net sales
Cost offset by grant							$ 300,000	$ 400,000	1,100,000	$ 1,000,000
National Institutes Of Health [Member] | Grant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net sales									1,600
Grant received funding		$ 1,400	$ 1,400						$ 6,400
Chairman Of Board Of Director [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other borrowings					$ 1,000,000
Unaffiliated Shareholders [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other borrowings					$ 1,200,000,000
Number of unaffiliated shareholders					two
Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued upon right offering	11,500,000			4,650,000		7,500,000
Share price (in dollars per share)	$ 5			$ 6		$ 1
Proceeds from issuance or sale of equity, total	$ 53,300,000			$ 24,500,000		$ 6,700,000,000
Second Sight Switzerland Sarl [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share price (in dollars per share)							100.00%		100.00%		99.50%
Second Sight Switzerland Sarl [Member] | Executive Officer [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Noncontrolling interest, ownership percentage by noncontrolling owners							0.50%		0.50%

Basis of Presentation, Signif_3

Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)	9 Months Ended
	Sep. 30, 2021USD ($)
Product Information [Line Items]
Reverse stock split	1-for-8
Severance payments	$ 200
Argus II Product [Member]
Product Information [Line Items]
Asset Impairment Charges	700,000
Argus II Product [Member] | Inventories [Member]
Product Information [Line Items]
Asset Impairment Charges	$ 500,000

Concentration of Risk (Details

Concentration of Risk (Details Narrative) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Assets	$ 73,630,000	$ 4,460,000
Eyes Second Sight Switzerland Sarl [Member]
Assets	$ 32,000	$ 18,000

Assets measured at fair value o

Assets measured at fair value on a recurring basis are as follows (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	$ 71,970	$ 3,122
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	71,970	3,122
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds

Property and equipment consiste

Property and equipment consisted of the following (in thousands): (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 653	$ 653
Accumulated depreciation and amortization	(536)	(479)
Property and equipment, net	117	174
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	584	584
Computer Hardware And Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 69	$ 69

Contract liabilities consisted

Contract liabilities consisted of the following (in thousands): (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Beginning balance	$ 335
Consideration received in advance of revenue recognition
Revenue recognized
Ending balance	$ 335

A summary of activity of our wa

A summary of activity of our warranty liabilities, which are included in accrued expenses, for the period ended September 30, 2021 is presented below: (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Beginning balance	$ 200
Additions
Settlements
Adjustments and other	(7)
Ending balance	$ 193

The Company evaluated the lease

The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company’s right-of-use assets and related lease liabilities are as follows (in thousands, except for remaining lease term and discount rate): (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
2021 (3 months remaining)	$ 51		$ 51
2022	201		201
2023	52		52
Total lease payments	304		304
Less imputed interest	(23)		(23)
Total lease liabilities	281		281
Current operating lease liabilities	179		179
Long term operating lease liabilities	102		102
Total lease liabilities	$ 281		$ 281
Discount rate	10.00%		10.00%
Cash paid for operating lease liabilities	$ 51	$ 48	$ 119	$ 275

Selected Balance Sheet Detail_2

Selected Balance Sheet Detail (Details Narrative)	Jan. 22, 2021USD ($)ft²	May 18, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 08, 2020USD ($)
Estimated incremental borrowing rate			10.00%
Non-cash lease expense			$ 11,000	$ 3,000
Right-of-use assets, net			270,000
Rent expense			146,000	277,000
Lessor [Member]
Termination date of the lease		Jun. 18, 2020
Non-cash lease expense		$ 210,730
Early lease termination fee		150,000
Payments for base rent subject to early termination		$ 900
Right-of-use assets, net			$ 2,300
Accrued termination fee				$ 150,000
Net Rentable Area | ft²	17,290
Sub-lease description	The sub-lease is for two years and two months.
Lessor [Member] | Minimum [Member]
Operating lease payments	$ 17,000
Lessor [Member] | Maximum [Member]
Operating lease payments	$ 17,500
Unsecured Promissory Note Payable [Member]
Interest rate on unsecured Promissory Note						12.00%
Chairman Of Board Of Director [Member]
Other borrowings						$ 1,000,000

As of September 30, 2021 and 20

As of September 30, 2021 and 2020, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common s (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	7,873	8,322
Warrants Issued To Underwriter In Connection With May 2020 Offering [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	10	375
Warrants Issued To Underwriter In Connection With March 2020 Offering [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	1,706	1,706
Warrants Issued To Underwriter In Connection With Feb 2019 Offering [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	5,975	5,976
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	182	265

A summary of warrants activity

A summary of warrants activity for the nine months ended September 30, 2021 is presented below (in thousands, except per share and contractual life data). (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Outstanding at End	10,125
Warrant [Member]
Class of Warrant or Right [Line Items]
Outstanding at Beginning	7,759,000
Outstanding at Beginning	$ 11.66
Outstanding at End	2 years 5 months 16 days	3 years 2 months 16 days
Exercised	(68,000)
Exercised	$ 1.45
Outstanding at End	7,691,000	7,759,000
Outstanding at Ending	$ 11.75	$ 11.66
Exercisable at End	7,691,000
Exercisable at ending	$ 11.75
Exercisable at Ending	2 years 5 months 16 days

Warrants (Details Narrative)

Warrants (Details Narrative)	May 05, 2020$ / sharesshares	Feb. 22, 2019$ / sharesshares	Feb. 15, 2019shares	Mar. 06, 2017$ / sharesshares	Dec. 31, 2019USD ($)	Sep. 30, 2021shares
Subsidiary, Sale of Stock [Line Items]
[custom:ClassOfWarrantOrRightIssuedDuringPeriod]	375,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.25
Warrants expiration date	May 5, 2025
Number of warrant outstanding						10,125
March2017 [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrants issued			1,700
Adjustments to Additional Paid in Capital, Warrant Issued | $ | $					$ 1,600
March2017 Before extention [Member] | Measurement Input, Risk Free Interest Rate [Member]
Subsidiary, Sale of Stock [Line Items]
Alternative investment, measurement input			0.0250
March2017 Before extention [Member] | Measurement Input, Price Volatility [Member]
Subsidiary, Sale of Stock [Line Items]
Alternative investment, measurement input			0.81
March2017 Before extention [Member] | Measurement Input, Expected Dividend Rate [Member]
Subsidiary, Sale of Stock [Line Items]
Alternative investment, measurement input			0
March2017 After extention [Member] | Measurement Input, Risk Free Interest Rate [Member]
Subsidiary, Sale of Stock [Line Items]
Alternative investment, measurement input			0.0249
March2017 After extention [Member] | Measurement Input, Price Volatility [Member]
Subsidiary, Sale of Stock [Line Items]
Alternative investment, measurement input			0.82
Right Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued upon right offering		5,976,000		1,706,000
Share price (in dollars per share) | $ / shares		$ 5.792		$ 11.76
Additional share price (in dollars per share) | $ / shares | $ / shares		$ 11.76
Term of warrants		5 years
Right Offering [Member] | March2017 [Member]
Subsidiary, Sale of Stock [Line Items]
Term of warrants			2 years

A summary of stock option activ

A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the nine months ended September 30, 2021 is presented below (in thousands, except per share and contractual life data). (Details) - Share-based Payment Arrangement, Option [Member] - The 2011 Equity Incentive Plan Member - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding, number of shares (in shares)	196
Options outstanding, weighted average exercise price (in dollars per share)	$ 15.48
Options outstanding, weighted average remaining contractual life (Year)	6 years 10 months 3 days	7 years 7 months 24 days
Forfeited or expired, number of shares (in shares)	(14)
Forfeited or expired, weighted average exercise price (in dollars per share)	$ 12.95
Options outstanding, number of shares (in shares)	182	196
Options outstanding, weighted average exercise price (in dollars per share)	$ 15.68	$ 15.48
Options exercisable, number of shares (in shares)	143
Options exercisable, weighted average exercise price (in dollars per share)	$ 18.82
Options exercisable, weighted average remaining contractual life (Year)	6 years 5 months 12 days

Stock-based compensation expens

Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 was as follows (in thousands): (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Research and development	$ 19	$ 27	$ 57	$ 394
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Research and development	5	11	15	120
Clinical And Regulatory [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Research and development	9	12	27	39
Selling And Marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Research and development				41
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Research and development	$ 5	$ 4	$ 15	$ 194

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative)	9 Months Ended
	Sep. 30, 2021USD ($)shares
The 2011 Equity Incentive Plan Member
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value of stock options exercisable	$ 15,000
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 105,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 2 months 23 days
The 2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares | shares	77,031

Litigation, Claims and Assess_2

Litigation, Claims and Assessments (Details Narrative) - USD ($)	Jul. 19, 2021	May 19, 2021	Apr. 02, 2021	Mar. 31, 2021	Sep. 30, 2021
Loss contingency, damages paid, value				$ 1,000,000	$ 1,000,000
Demanded damages, value		$ 6,162,760
Other damages	$ 2,000,000
Oppenheimer And Co Inc [Member]
Invoice amount, receivable			$ 1,860,000
Business combination, commission percentage			6.50%
Private placement, amount raised			$ 27,900,000
Euro Member Countries, Euro
Demanded damages, value		$ 5,217,659.60